{
    "Symbol": "GMAB",
    "AssetType": "Common Stock",
    "Name": "Genmab AS",
    "Description": "Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.",
    "CIK": "1434265",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "TOLDBODGADE 33, 1253 COPENHAGEN K, DK",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "18104451000",
    "EBITDA": "5951000000",
    "PERatio": "23.62",
    "PEGRatio": "1.273",
    "BookValue": "498.87",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "1.2",
    "RevenuePerShareTTM": "27.24",
    "ProfitMargin": "0.307",
    "OperatingMarginTTM": "0.193",
    "ReturnOnAssetsTTM": "0.106",
    "ReturnOnEquityTTM": "0.183",
    "RevenueTTM": "17782999000",
    "GrossProfitTTM": "14595000000",
    "DilutedEPSTTM": "1.2",
    "QuarterlyEarningsGrowthYOY": "4.883",
    "QuarterlyRevenueGrowthYOY": "0.452",
    "AnalystTargetPrice": "41.53",
    "AnalystRatingStrongBuy": "2",
    "AnalystRatingBuy": "3",
    "AnalystRatingHold": "5",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "23.62",
    "ForwardPE": "26.04",
    "PriceToSalesRatioTTM": "1.173",
    "PriceToBookRatio": "4.185",
    "EVToRevenue": "0.935",
    "EVToEBITDA": "2.585",
    "Beta": "0.828",
    "52WeekHigh": "39.53",
    "52WeekLow": "24.53",
    "50DayMovingAverage": "27.13",
    "200DayMovingAverage": "29.16",
    "SharesOutstanding": "634659000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}